ArticleTranslational oncology2026
Integrative single-cell and machine learning analysis identifies a tumor doubling time-related prognostic signature and therapeutic targets in head and neck squamous cell carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) exhibits marked molecular heterogeneity and diverse clinical outcomes, partly influenced by HPV status and the tumor immune microenvironment. Although tumor doubling time (TDT) reflects tumor growth kinetics and has prognostic relevance, its molecular basis in HNSCC remains unclear.
methodsSingle-cell RNA-seq data from GSE164690 were integrated with bulk transcriptomic datasets from TCGA-HNSC, GSE41613, GSE65858, and ICGC. We identified 21 tumor doubling time-related genes (TDTRGs), evaluated their cell type-specific enrichment using UCell, and defined molecular subtypes by consensus clustering. Immune infiltration was assessed by ssGSEA and CIBERSORT. A prognostic model was developed using 117 machine-learning algorithm combinations in the Mime1 package and further evaluated by single-cell visualization, cell cycle scoring, pseudotime analysis, drug sensitivity prediction, and molecular docking.
resultsA single-cell atlas comprising 17 cell populations was constructed. TDTRGs were mainly enriched in cycling T cells and epithelial cells and showed HPV-related expression differences. Two molecular subtypes were identified; C2 was associated with poorer progression-free interval (P = 0.001) and enrichment of MET and integrin signaling. A seven-gene signature-CCBE1, MAD2L1, ECT2, BIRC5, ITGA6, ESM1, and NUF2-showed robust prognostic performance across independent cohorts and outperformed 73 published signatures. Single-cell and pseudotime analyses confirmed cell type-specific and dynamic regulation. Venetoclax was predicted as a potential therapeutic candidate, with docking energies below -9 kcal·mol⁻¹.
conclusionThis study defines TDTRG-related heterogeneity in HNSCC and establishes a robust seven-gene prognostic signature, providing potential biomarkers and therapeutic insights for personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.